Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy

NCT05113537 is registered in ClinicalTrials.gov with Vadim S Koshkin as lead sponsor.

NCT NCT05113537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05113537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy
Lead sponsor
Vadim S Koshkin
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 8, 2022
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic castration-resistant prostate cancer, metastatic castration-resistant prostate carcinoma, metastatic prostate adenocarcinoma, stage iv prostate cancer ajcc v8, stage iva prostate cancer ajcc v8, stage ivb prostate cancer ajcc v8